Home > Insider Trading > Filing (0001179110-19-008261)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1679363	Morphic Holding Inc.	MORF	Pharmaceutical Preparations (2834)	473878772

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1721017	Vikas Goyal	C/O Sr One, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-01	1,469,950	$0.00	1,469,950	No	4	C	Indirect	By S.R. One, Limited
Common Stock	Acquisiton	2019-07-01	830,489	$0.00	2,300,439	No	4	C	Indirect	By S.R. One, Limited
Common Stock	Acquisiton	2019-07-01	333,333	$15.00	2,633,772	No	4	P	Indirect	By S.R. One, Limited

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By S.R. One, Limited
No	4	C	Indirect	By S.R. One, Limited
No	4	P	Indirect	By S.R. One, Limited

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-07-01	1,469,950	$0.00	1,469,950	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-07-01	830,489	$0.00	830,489	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Vikas Goyal holds the title of Principal at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.